

**11410**

ABOZANTINIB VERSUS PLACEBO FOR ADVANCED **NEUROENDOCRINE** TUMORS (NET) AFTER PROGRESSION ON PRIOR THERAPY (CABINET TRIAL/ALLIANCE A021602): UPDATED RESULTS INCLUDING PROGRESSION FREE-SURVIVAL (PFS)

**LBA2**

POD1UM-303/INTERAACT 2: PHASE 3 STUDY OF RETIFANLIMAB WITH CARBOPLATIN PACLITAXEL (C-P) IN PATIENTS (PTTS) WITH INOPERABLE LOCALLY RECURRENT OR METASTATIC CARCINOMA OF THE **ANAL** CANAL (SCAC) NOT PREVIOUSLY TREATED WITH SYSTEMIC CHEMOTHERAPY

**5040**

IMHOTEP PHASE II TRIAL OF NEOADJUVANT PEMBROLIZUMAB IN DMMR/MSI TUMORS: RESULTS OF THE **COLORECTAL** CANCER COHORT

**LBA24**

NEOADJUVANT IMMUNOTHERAPY IN LOCALLY ADVANCED MMR-DEFICIENT **COLON** CANCER: 3-YEAR DISEASE-FREE SURVIVAL FROM NICHE-2

**LBA58**

RANDOMIZED PHASE III TRIAL OF PERIOPERATIVE CHEMOTHERAPY WITH OR WITHOUT PREOPERATIVE CHEMORADIOTHERAPY (PREOP CRT) FOR RESECTABLE **GASTRIC** CANCER (AGITG TOPGEAR)

**LBA60**

PHASE 3 STUDY OF SHR-1701 VERSUS PLACEBO IN COMBINATION WITH CHEMO AS FIRST-LINE (1L) THERAPY FOR HER2-NEGATIVE **GASTRIC/GASTROESOPHAGEAL** JUNCTION ADENOCARCINOMA

**LBA62**

PREOPERATIVE MODIFIED FOLFIRINOX (MFOLFIRINOX) WITH OR WITHOUT CHEMORADIATION (CRT) IN BORDERLINE RESECTABLE **PANCREATIC** CANCER (BRPC): RESULTS FROM THE RANDOMIZED PHASE II PANDAS/PRODIGE 44

**LBA3**

TACE WITH OR WITHOUT LENVATINIB (LEN) + PEMBROLIZUMAB (PEMBRO) FOR INTERMEDIATE-STAGE **HEPATOCELLULAR** CARCINOMA (HCC): PHASE 3 LEAP-012 STUDY

**LBA59**

MODIFIED FOLFOX PLUS/MINUS NIVOLUMAB AND IPILIMUMAB VS FLOT PLUS NIVOLUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC ADENOCARCINOMA OF THE **STOMACH** OR **GASTROESOPHAGEAL** JUNCTION – FINAL RESULTS OF THE IKF-AIO-MOONLIGHT TRIAL

**LBA25**

RANDOMIZED PHASE III TRIAL OF RAMUCIRUMAB IN COMBINATION WITH TAS102 (TRIFLURIDIN/TIPIRACIL) VS. TAS102 MONOTHERAPY IN HEAVILY PRETREATED METASTATIC **COLORECTAL CANCER**: THE RAMTAS/IKF643 TRIAL

Leads



Dr McCollom  
Med Onc



Dr Akkus  
Med Onc



Dr Morgan  
Clin Onc